Document Detail

Primary mediastinal large B-cell lymphoma: a single-institution clinical study in Japan.
MedLine Citation:
PMID:  15239397     Owner:  NLM     Status:  MEDLINE    
Several clinicopathologic studies of primary mediastinal large B-cell lymphoma (Med-DLBCL) have been reported from Western countries; however, only a few series of at most 10 cases are available in Japan. To further clarify the Med-DLBCL occurring in Japan, we analyzed the clinical features of 28 patients with Med-DLBCL diagnoses who were treated at the National Cancer Center Hospital between 1982 and 2002. The median age was 37 years (range, 18-80 years). The ages of 16 male patients ranged widely from 18 to 80 years, whereas the 12 female patients appeared to show a single age peak at 20 to 40 years. Only 13 patients (46%) achieved a complete response with initial treatments, mostly by CHOP-like regimens (cyclophosphamide, doxorubicin, vincristine [Oncovin], and prednisolone) followed by radiotherapy. The estimated 3-year overall and failure-free survival rates were 32% and 33%, respectively, indicating the relatively unfavorable prognosis of the patients in our series. The following factors were found to be significantly associated with shortened survival prospects: age >60 years, serum lactate dehydrogenase level greater than normal, performance status >1, and presence of bulky mediastinal mass. In conclusion, the clinical features of Japanese patients with Med-DLBCL may be different from those with the disease in Western countries. Because this investigation was a single-institution study with a limited number of patients, however, multicenter confirmatory studies are needed.
Naohiro Sekiguchi; Junko Nishimoto; Kazuki Tanimoto; Shigeru Kusumoto; Yasushi Onishi; Takashi Watanabe; Yukio Kobayashi; Hisao Asamura; Yoshikazu Kagami; Yoshihiro Matsuno; Kensei Tobinai
Related Documents :
22058187 - Therapeutic advances in non-small cell lung cancer.
21807637 - A polymorphic -844t/c in fasl promoter predicts survival and relapse in non-small cell ...
12234697 - Remediastinoscopy after neoadjuvant therapy for non-small cell lung cancer.
23892527 - The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postop...
18440487 - Role of the width of the surgical margin in a hepatectomy for small hepatocellular carc...
6864907 - Treatment of renal cancer patients by transcatheter embolization and its effects on lym...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of hematology     Volume:  79     ISSN:  0925-5710     ISO Abbreviation:  Int. J. Hematol.     Publication Date:  2004 Jun 
Date Detail:
Created Date:  2004-07-08     Completed Date:  2004-07-20     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9111627     Medline TA:  Int J Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  465-71     Citation Subset:  IM    
Hematology Division, National Cancer Center Hospital, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / administration & dosage,  therapeutic use*
Cyclophosphamide / administration & dosage
Disease-Free Survival
Doxorubicin / administration & dosage
Lymphoma, B-Cell / drug therapy,  pathology*
Lymphoma, Large B-Cell, Diffuse / drug therapy,  pathology*
Mediastinal Neoplasms / drug therapy,  pathology*
Middle Aged
Prednisolone / administration & dosage
Retrospective Studies
Sex Factors
Vincristine / administration & dosage
Reg. No./Substance:
0/VAP-cyclo protocol; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 50-24-8/Prednisolone; 57-22-7/Vincristine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Extramedullary relapse confirmed by fluorescence in situ hybridization study of an ear mass in acute...
Next Document:  Sustained remissions with long-term weekly chlorambucil maintenance therapy in patients with mucosa-...